Search

Your search keyword '"Carlos Henrique Suzuki Bellucci"' showing total 2 results
Start Over Author "Carlos Henrique Suzuki Bellucci" Journal the scientific world journal
2 results on '"Carlos Henrique Suzuki Bellucci"'

1. Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Author

René Arnouk, Carlos Henrique Suzuki Bellucci, Roberto Benatuil Stull, José de Bessa Junior, Cesar Augusto Malave, and Cristiano Mendes Gomes

Subjects
Technology, Medicine, Science
Abstract

Purpose. To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH). Materials and Methods. Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups. Results. Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Qmax and PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups. Conclusions. Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.

Published
2012
Full Text
View/download PDF

2. Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Author

Carlos Henrique Suzuki Bellucci, René Arnouk, José de Bessa Júnior, Cesar Augusto Malave, Roberto Benatuil Stull, and Cristiano Mendes Gomes

Subjects
Male, medicine.medical_specialty, Article Subject, Urinalysis, Urology, Prostatic Hyperplasia, lcsh:Medicine, urologic and male genital diseases, lcsh:Technology, General Biochemistry, Genetics and Molecular Biology, law.invention, Injections, Randomized controlled trial, Prostate, law, Medicine, Humans, Prospective Studies, Botulinum Toxins, Type A, Prospective cohort study, Adverse effect, lcsh:Science, General Environmental Science, Aged, medicine.diagnostic_test, Botulinum Neurotoxin Type A, business.industry, lcsh:T, lcsh:R, General Medicine, Organ Size, Hyperplasia, Middle Aged, Prostate-Specific Antigen, medicine.disease, Prostate-specific antigen, medicine.anatomical_structure, Treatment Outcome, Clinical Study, Kallikreins, lcsh:Q, business
Abstract

Purpose. To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH).Materials and Methods. Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups.Results. Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Qmaxand PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups.Conclusions. Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results